Pricing Log in Create free account
Friday 6 November 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

LGND Healthcare Biotechnology

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue
−31.8%
EPS
−123.9%
Free cash flow
−268.5%
Total debt
+52.6%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%
Market cap
$6.0B
P/E
116×
Fwd P/E
88.3×
Dividend yield
—
F-score
6/9
Altman Z
5.45
Beneish M
−4.02
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Ligand Pharmaceuticals Incorporated (LGND) valuation and DCF model

What the price implies · reverse DCF

At $306.43 the price implies free cash flow after share-based pay growing 42.1% a year for ten years.

Free cash flow after share-based pay grew −0.5% a year over the last ten years, −3.7% over the last five. The price asks for 42.7 points a year more than its ten-year rate. The industry’s median company is priced for 27.5%.

In December 2017 the price assumed 15.1% a year; Ligand Pharmaceuticals Incorporated went on to grow free cash flow after share-based pay −38.2% a year to FY2025.

Price implies
42.1%
Last 5 years, reported
−3.7%
Last 10 years, reported
−0.5%
Industry median implies
27.5%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
42.1% a year for ten years
$306.43
today’s price
Its base case
−0.5% a year for five years, then −0.3%
$4.44
98.6% below today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Ligand Pharmaceuticals Incorporated’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 42.1% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Ligand Pharmaceuticals Incorporated’s own cost of capital: risk-free 4.3% + beta 1.21 × equity premium 4.5% = 9.7% cost of equity; weighted, 9.7%.

Use 9.7%
Equity value $90.91m ▼ below market cap $6.28b
Base case value per share $4.44 equity value ÷ 20.49m shares
Current price $306.43 market price per share
Below today’s price 98.6% downside at the base case’s assumptions

How we got there$144.62m 10 years of cash to equity+$147.19m terminal value−$200.91m net debt=$90.91m equity value÷20.49m shares=$4.44 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Biotechnology).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 115.97× 40.76× 54.52× 113% above 10.26× 1030% above
P/FCF 58.00× 35.24× 29.86× 94% above 24.81× 134% above
P/B 6.23× 3.17× 3.03× 106% above 2.05× 204% above
EV/EBITDA 109.42× 70.14× 40.72× 169% above 0.65× 16707% above
EV/Sales 24.72× 12.40× 10.72× 131% above 8.98× 175% above
P/E P/FCF P/B EV/EBITDA EV/Sales
20.15×63.47×106.79×150.12×10Y avg 54.52×2017201820192021202320252026

LGND trades at 115.97× P/E, against a 10-year average of 54.52× (range 2.41×–163.60×). That is dearer than 83% of the last 6 year-end readings; re-rating to the average implies $144.05 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.